Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network
January 21, 2025 08:30 ET
|
Adaptive Research Inc
Adaptive Research announced that Prodigy Psychiatric Group has joined its clinical trial network, marking Adaptive Research's expansion into psychiatry.
Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction
January 09, 2025 08:00 ET
|
Amwell
Amwell divests virtual psychiatric care business to Avel eCare in all-cash transaction
Fulfilling the Promise of Noninvasive Brain Stimulation as a Precision Medicine Tool
January 08, 2025 10:47 ET
|
Brain & Behavior Research Foundation
New York, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Fulfilling the Promise of Noninvasive Brain Stimulation as a Precision...
Buckingham Psychiatry Unveils a New Way to Get Help via an Online Patient Portal
January 06, 2025 09:50 ET
|
Buckingham Psychiatry
DOYLESTOWN, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- As a general psychiatrist serving the Philadelphia area, Dr. Jacob Buinewicz is always seeking ways to better engage with patients and provide...
Online Therapy Service for Teenagers Market Experiences Robust Growth, Surpassing $80 Billion in 2024, Driven by Innovative Online Therapy Models and Increased Awareness - Long-term Forecast to 2033
January 03, 2025 06:39 ET
|
Research and Markets
Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Online Therapy Service for Teenagers Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The online therapy service market...
Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics
December 05, 2024 04:02 ET
|
Magstim EGI
UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.
ADHD: What You Need to Know
November 19, 2024 10:00 ET
|
Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development
November 14, 2024 10:06 ET
|
Sparian Biosciences, Inc
Sparian Biosciences announced that it has been awarded a $19.5 million, five-year grant to fund development of SBS-226
Sparian Biosciences Announces Formation of its Science Advisory Board
November 13, 2024 13:01 ET
|
Sparian Biosciences, Inc
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board...
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
November 12, 2024 10:01 ET
|
Sparian Biosciences, Inc
Sparian Biosciences announced results from the Phase 1 clinical trial of the first in class novel AEAr agonist analgesic SBS-1000.